A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Cenicriviroc for the treatment of liver fibrosis in adult subjects with nonalcoholic steatohepatitis.
Enrollment Status: OPEN
This is a phase 3 study for patients with Stage 2 or Stage 3 fibrotic liver disease to evaluate the safety and effectiveeness of Cenicriviroc. The study has two (2) parts and lasts from five (5) to seven (7) years. To be qualified for the study, participants will need to complete one screening visit and one baseline visit. During those visits, particpants will be asked about their medical history, medication use, obtain vitals signs and laboratory blood draws, undergo a fibroscan, liver biopsy, physical exam and electrocardiogram (EKG or ECG). Patients who pass the screening and baseline visits will be enrolled into the study to receive either an oral placebo medication or oral Cenicriviroc medication in both Parts 1 and 2 of the trial. Because this is a double blind study, the physician, research staff nor the patient will know which medication they receive. Participants have a greater than 65% chance of receiving the study medication (Cenicriviroc). As with all clinical research trials, participants may discontiue study drug and withdrawal from the trial at anytime without penalty to your